SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus, the applicable prospectus supplement and any free writing prospectus may contain forward-looking statements, including with respect to our plans, objectives, and expectations for our business, operations, and financial performance and condition. Any statements contained herein or therein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “due,” “estimate,” “expect,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language. Forward-looking statements include, but are not limited to, statements about:
•
our ability to successfully enter new markets or develop product candidates, including the expected timing and results of investigational studies and preclinical and clinical trials, and our research and development programs;
•
the timing or likelihood of regulatory filings for any product candidates we develop and our ability to obtain and maintain regulatory approvals for such product candidates for any indication;
•
our intentions and ability to successfully commercialize our product candidates;
•
the rate and degree of market acceptance of any products developed by us;
•
our ability to successfully execute and achieve benefits from our recent leadership transition plan and organizational restructuring;
•
our efforts to hold or generate significant operating capital, including through partnering, potential asset sales of our non-healthcare assets, and operating cost reductions;
•
our cash position;
•
any delays or potential delays to our clinical trials as a result of the COVID-19 pandemic;
•
our estimates regarding expenses, future revenue, capital requirements, and our need for additional financing;
•
our strategy and overall approach to our business model, including our efforts to focus our business in the healthcare industry;
•
our ability to adapt to changes in laws, regulations, and policies;
•
our reliance on and the performance of third parties, including exclusive channel collaborations and joint ventures;
•
competition from existing technologies and products or new technologies and products that may emerge;
•
our expectations related to the use of proceeds from our public offerings and other financing efforts;
•
actual or anticipated variations in our operating results;
•
market conditions in our industry;
•
our ability to retain, recruit, and train key personnel, or the loss of key personnel as a result of illness or otherwise;
•
our ability to successfully enter into optimal strategic relationships with our subsidiaries and operating companies that we may form in the future;
•
the result of litigation proceedings or investigations that we currently face or may face in the future;
•
the effects, duration, and severity of the ongoing COVID-19 pandemic and the actions we and others have taken or may take in response; and
•
our intended use of the proceeds from sales of securities by us.
These statements are based on management’s current expectations, estimates, forecasts and projections about our business and industry, are not guarantees of future performance and involve known and unknown